Earnings release
Page 1
Exhibit 99.1 Teknova Reports Third Quarter 2026 Financial Results Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year Company raises 2026 revenue guidance to $46-48 million Strengthened balance sheet with $46 million public equity offering completed in October 2026 HOLLISTER, Calif., November 4, 2026 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2026. “We posted record revenue for the second consecutive quarter,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers. Notably, there was an increase in purchases of our custom products by small and mid-sized biotech customers and their associated contract manufacturers, which we believe is an early indication of biotech funding improvements over the past four quarters.” Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered excellent financial results in the third quarter 2026 compared to 2025, highlighted by 22% revenue growth and a significant improvement in Adjusted EBITDA and Free Cash Outflow. We are therefore raising our 2026 revenue guidance to $46-48 million and maintaining our expectations for full-year Free Cash Outflow of less than $8 million,” he explained. “We are also pleased with the balance sheet flexibility we achieved with our $46 million equity capital raise in October and that we were able to welcome a significant number of new investors to Teknova’s shareholder base through the offering,” he added. Corporate and Financial Updates • Third quarter 2026 total revenue of $12.7 million, up 22% compared to $10.5 million for the third quarter 2025 • On October 22, 2026, closed an underwritten public offering of 9,200,000 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $5.00 per share, for gross proceeds of $46.0 million and net proceeds of approximately $42.9 million • Total cash and short-term investments were $16.6 million and total borrowings were $13.2 million at the end of the third quarter 2026 • Expanded its modular manufacturing platform with the launch of the Fill-Tek™ Dispensing System, which provides greater flexibility for customers to order the exact single-use bag sizes, quantities, and fill volumes their process requires across RUO, RUO+, and GMP grades, with no added turnaround time
Page 2
Revenue for the Third Quarter 2026 For the Three Months Ended September 30, For the Nine Months Ended September 30, (Dollars in thousands) 2026 2025 2026 2025 Lab Essentials $ 9,034 $ 8,308 $ 26,613 $ 24,217 Clinical Solutions 3,168 1,706 7,741 4,928 Other 502 440 1,612 1,391 Total revenue $ 12,704 $ 10,454 $ 35,966 $ 30,536 Third Quarter 2026 Financial Results Total revenue for the third quarter 2026 was $12.7 million, up 22% compared to $10.5 million in the third quarter 2025. Lab Essentials revenue was $9.0 million in the third quarter 2026, up 9% compared to $8.3 million in the third quarter 2025. Clinical Solutions revenue was $3.2 million in the third quarter 2026, up 86% compared to $1.7 million in the third quarter 2025. Gross profit for the third quarter 2026 was $4.8 million, compared to $3.2 million in the third quarter 2025. Gross margin for the third quarter 2026 was 38.0%, compared to 30.7% in the third quarter 2025. The increase in gross margin was primarily driven by higher revenue and, to a lesser extent, lower fixed cost absorption into cost of goods sold from changes in finished goods inventory levels, partially offset by higher variable costs. Operating expenses for the third quarter 2026 were $8.0 million, compared to $7.2 million in the third quarter 2025. The increase was primarily driven by higher spending in sales and marketing, a result of higher headcount, coupled with slightly increased general and administrative expenses, partially offset by lower stock-based compensation expense. Net loss for the third quarter 2026 was $3.5 million, or negative $0.06 per diluted share, compared to $4.3 million, or negative $0.08 per diluted share, for the third quarter 2025. Adjusted EBITDA for the third quarter 2026 was negative $1.0 million, compared to negative $1.6 million for the third quarter 2025. Cash used in operating activities for the third quarter 2026 was $1.3 million, compared to $2.0 million of cash used in operating activities for the third quarter 2025. Free Cash Outflow was $1.4 million for the third quarter 2026, compared to $2.4 million for the third quarter 2025. A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release. 2026 Outlook Teknova raises its fiscal 2026 outlook for revenue and reaffirms its fiscal 2026 outlook for Free Cash Outflow. The Company now anticipates total revenue of $46 million to $48 million for the fiscal year ending December 31, 2026 (“2026”). The Company continues to anticipate Free Cash Outflow of less than $8 million for 2026. Upcoming Investor Conference Attendance Craig-Hallum Alpha Select Conference (New York, NY) November 17, 2026 Stephens Annual Investment Conference (Nashville, TN) November 18, 2026
Page 3
Conference Call and Webcast Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event. About Teknova Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies. Non-GAAP Financial Measures This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow (Outflow). Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance. Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activities less purchases of property, plant, and equipment. Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
Page 4
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release. Forward-Looking Statements Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which Teknova makes only as of the date hereof, even if they are repeated by Teknova subsequently. Teknova does not intend and shall have no obligation to update, amend, or clarify these forward-looking statements, except as may be required under applicable securities laws. Investor Contact Matt Lowell Chief Financial Officer matt.lowell@teknova.com +1 831-637-1100 Media Contact Jennifer Henry Senior Vice President, Marketing jenn.henry@teknova.com +1 831-313-1259
Page 5
ALPHA TEKNOVA, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2026 2025 2026 2025 Revenue $ 12,704 $ 10,454 $ 35,966 $ 30,536 Cost of sales 7,878 7,248 22,471 20,339 Gross profit 4,826 3,206 13,495 10,197 Operating expenses: Research and development 581 542 1,744 1,675 Sales and marketing 2,348 1,747 6,598 4,960 General and administrative 4,816 4,647 14,686 15,068 Amortization of intangible assets 287 287 861 861 Total operating expenses 8,032 7,223 23,889 22,564 Loss from operations (3,206) (4,017) (10,394) (12,367) Other expenses, net Interest expense, net (259) (190) (730) (499) Other adjustment to loan exit fee — — — 485 Other income 9 — 20 — Total other expenses, net (250) (190) (710) (14) Loss before income taxes (3,456) (4,207) (11,104) (12,381) Provision for income taxes 34 79 111 120 Net loss $ (3,490) $ (4,286) $ (11,215) $ (12,501) Net loss per share—basic and diluted $ (0.06) $ (0.08) $ (0.21) $ (0.23) Weighted average shares used in computing net loss per share—basic and diluted 53,694,378 53,516,986 53,641,532 53,462,768
Page 6
ALPHA TEKNOVA, INC. Condensed Balance Sheets (Unaudited) (In thousands) As of September 30, As of December 31, 2026 2025 ASSETS Current assets: Cash and cash equivalents $ 6,631 $ 5,912 Short-term investments, held-to-maturity 9,929 15,426 Accounts receivable, net 5,820 4,618 Inventories, net 7,477 7,054 Prepaid expenses and other current assets 1,942 1,501 Total current assets 31,799 34,511 Property, plant, and equipment, net 38,086 41,733 Operating right-of-use lease assets 12,641 14,112 Intangible assets, net 11,082 11,943 Other non-current assets 1,076 1,285 Total assets $ 94,684 $ 103,584 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,813 $ 1,378 Accrued liabilities 5,111 4,283 Current portion of operating lease liabilities 2,002 1,876 Total current liabilities 8,926 7,537 Deferred tax liabilities 989 879 Long-term debt, net 13,269 13,123 Long-term operating lease liabilities 11,716 13,270 Total liabilities 34,900 34,809 Stockholders’ equity: Preferred stock — — Common stock 1 1 Additional paid-in capital 206,788 204,564 Accumulated deficit (147,005) (135,790) Total stockholders’ equity 59,784 68,775 Total liabilities and stockholders’ equity $ 94,684 $ 103,584
Page 7
ALPHA TEKNOVA, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2026 2025 2026 2025 Operating activities: Net loss $ (3,490) $ (4,286) $ (11,215) $ (12,501) Adjustments to reconcile net loss to net cash used in operating activities: Bad debt expense 3 22 8 71 Inventory reserve 355 732 1,180 1,657 Depreciation and amortization 1,589 1,591 4,758 4,761 Stock-based compensation 612 850 1,929 2,652 Deferred taxes 33 78 110 119 Accrued interest income on short-term investments 19 (62) 26 (8) Amortization of discount on short-term investments (92) (153) (237) (508) Amortization of debt financing costs 51 44 146 173 Other adjustment to loan exit fee — — — (485) Non-cash lease expense 14 31 43 92 Loss on disposal of property, plant, and equipment 68 — 92 19 Changes in operating assets and liabilities: Accounts receivable (415) (17) (1,210) (894) Inventories (921) (36) (1,603) (1,770) Prepaid expenses and other current assets (1,181) (1,424) (869) (1,464) Other non-current assets 51 33 209 67 Accounts payable 350 (136) 508 244 Accrued liabilities 1,676 753 1,017 (399) Other — — — (10) Cash used in operating activities (1,278) (1,980) (5,108) (8,184) Investing activities: Purchases of short-term investments (3,924) (3,973) (11,792) (13,708) Maturities of short-term investments 5,500 6,000 17,500 22,000 Purchases of property, plant, and equipment (120) (387) (466) (800) Cash provided by investing activities 1,456 1,640 5,242 7,492 Financing activities: Proceeds from long-term debt — — — 1,110 Payment of exit fee costs — — — (1,110) Proceeds from financed insurance premiums 428 333 428 333 Repayment of financed insurance premiums (41) (94) (138) (150) Proceeds from exercise of stock options 62 29 241 49 Proceeds from issuance of common stock under employee stock purchase plan — — 54 56 Payment of debt issuance costs — — — (100) Cash provided by financing activities 449 268 585 188 Change in cash and cash equivalents 627 (72) 719 (504) Cash and cash equivalents at beginning of period 6,004 3,276 5,912 3,708 Cash and cash equivalents at end of period $ 6,631 $ 3,204 $ 6,631 $ 3,204
Page 8
ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (Unaudited) (In thousands) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2026 2025 2026 2025 Net loss – as reported $ (3,490) $ (4,286) $ (11,215) $ (12,501) Add back: Interest expense, net (259) (190) (730) (499) Provision for income taxes 34 79 111 120 Depreciation expense 1,302 1,304 3,897 3,900 Amortization of intangible assets 287 287 861 861 EBITDA $ (1,608) $ (2,426) $ (5,616) $ (7,121) Other and non-recurring expenses: Stock-based compensation expense 612 850 1,929 2,652 Other adjustment to loan exit fee — — — (485) Adjusted EBITDA $ (996) $ (1,576) $ (3,687) $ (4,954) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2026 2025 2026 2025 Cash used in operating activities $ (1,278) $ (1,980) $ (5,108) $ (8,184) Purchases of property, plant, and equipment (120) (387) (466) (800) Free Cash Flow $ (1,398) $ (2,367) $ (5,574) $ (8,984)